UNCY
NASDAQ · Biotechnology
Unicycive Therapeutics Inc
$6.69
+0.50 (+8.08%)
Open$6.32
Previous Close$6.19
Day High$6.78
Day Low$6.32
52W High$5.07
52W Low$2.63
Volume—
Avg Volume582.0K
Market Cap143.78M
P/E Ratio—
EPS$-0.89
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
-6.3% upside
Current
$6.69
$6.69
Target
$6.27
$6.27
$3.63
$6.27 avg
$7.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 52.90M | 51.72M | 45.87M |
| Net Income | -11,930,457 | -10,903,389 | -10,566,816 |
| Profit Margin | -22.6% | -21.1% | -23.0% |
| EBITDA | -19,602,786 | -19,995,313 | -16,713,067 |
| Free Cash Flow | -9,449,797 | -9,177,412 | -10,735,832 |
| Rev Growth | -5.2% | +18.0% | +24.4% |
| Debt/Equity | 0.52 | 0.63 | 0.70 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |